Clinical trials: Metastatic Non-Small Cell Lung Cancer
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Lung Cancer
Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo
This study is intended for participants with advanced, not amenable to surgery, or metastatic lung cancer who have not received any prior chemotherapy.
- Trial name
- NCT00538681
- Testing
- enzastaurin, pemetrexed, cisplatin
- Where
- 12 sites in Belgium, Germany and 3 more
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Cancer Metastatic, Radiotherapy
Phase III, Multicenter, Randomized Controlled Clinical Study of Three-Dimensional Radiotherapy for Primary Tumors in Non-Oligometastatic Stage IV Non-Small Cell Lung Cancer
For patients with non-small cell lung cancer and more than five metastatic lesions (non-oligometastatic disease), does radical treatment of the primary lung lesion, in addition to pharmacotherapy, also provide benefits in terms…
- Trial name
- NCT07462728
- Testing
- Three-Dimensional Radiotherapy for Primary lungTumors
- Volunteers
- 200 people
- Sponsor
- Guizhou Medical University
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 42 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Endocrine Tumors, Non-Small Cell Lung Cancer
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible.
- Conditions
- Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03412877
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Volunteers
- 285 people
- Sponsor
- National Cancer Institute (NCI)
Urethral Neoplasms, Neoplasms, Urethral
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
Background: Gemcitabine and carboplatin are chemotherapy drugs used to treat several types of cancer, including cancer of the pancreas, bladder, ovaries, and lung.
- Conditions
- Urethral Neoplasms, Neoplasms, Urethral, Cancer of the Urethra, Urethral Cancer
- Trial name
- NCT01352962
- Testing
- Gemcitabine, Carboplatin, Lenalidomide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
This phase II clinical study is a study to explore the efficacy and safety of BL-B01D1 in combination with Osimertinib Mesylate Tablets in patients with histologically and/or cytologically confirmed locally advanced or metastatic…
- Trial name
- NCT06498986
- Testing
- BL-B01D1, Osimertinib Mesylate Tablets
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Lung Cancer, Head and Neck Cancer
Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
The main purpose of the study is to: Determine the safety and tolerability of erlotinib and LBH589B. Establish a recommended phase II expansion dosing of LBH589B and erlotinib in patients with advanced aerodigestive tract cancers.
- Trial name
- NCT00738751
- Testing
- Panobinostat (LBH589), erlotinib
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-Small Cell Lung Cancer, Lymph Node Metastasis
XR-Assisted PET/CT Navigation for Cervical Lymph Node Dissection in Lung Cancer
This single-arm, prospective feasibility study evaluates an Extended Reality (XR) headset-based preoperative surgical planning workflow that fuses 18F-FDG PET metabolic hotspots with CT anatomy on the OpVerse platform, in…
- Conditions
- Non-Small Cell Lung Cancer, Lymph Node Metastasis, Supraclavicular Lymph Node Metastasis
- Trial name
- XR-NeckLND (NCT07593872)
- Testing
- OpVerse XR Surgical Planning Platform with HoloLens HMD, Cervical / Supraclavicular Lymph Node Dissection
- Volunteers
- 10 people
- Sponsor
- National Taiwan University Hospital
NSCLC Stage IV, Brain Metastases
SRS Sequential Sindilimab in Brain Metastasis of NSLSC
A phase II study on the treatment of advanced non-small cell lung cancer with brain metastasis by SRS sequential sintilimab
- Conditions
- NSCLC Stage IV, Brain Metastases, SRS, Sintilimab
- Trial name
- NCT04180501
- Testing
- SRS sequential sintilimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Xiaorong Dong
Non Small Cell Lung Cancer, Breast Cancer
Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer.
- Conditions
- Non Small Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- PTC-IMPACT (NCT06227728)
- Where
- 2 sites in Vietnam
- Volunteers
- 50 people
- Sponsor
- Gene Solutions
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer
There is a growing body of evidence that implicates inflammation as a mechanism of disease progression and reduced survival in patients with advanced cancer.
- Trial name
- NCT02271581
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Leo W. Jenkins Cancer Center
Hepatocellular Carcinoma, Non-small Cell Lung Cancer Metastatic
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
This study is being done to look at how effective the drug, atezolizumab, with or without the drug bevacizumab, is for people with inoperable liver cancer or non-small lung cancer that has spread to the liver.
- Conditions
- Hepatocellular Carcinoma, Non-small Cell Lung Cancer Metastatic, Liver Metastases
- Trial name
- NCT04563338
- Testing
- Atezolizumab, Bevacizumab
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
Non-small Cell Lung Cancer (NSCLC)
Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment
The tumor treating fields（EFE-P100）generates alternating electric field during operation, and the tumor treating fields（EFE-P100）has a specific frequency and a specific field intensity.
- Trial name
- NCT05661240
- Testing
- Tumor treating fields（EFE-P100）, Docetaxel injection
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Stage IV Non-small Cell Lung Cancer
Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
Current therapies for Stage IV non-small cell lung cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV lung…
- Trial name
- NCT00003497
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Burzynski Research Institute
Dyspnea, Lung Cancer
Study of Episodic Breathlessness in Patients With Lung Cancer or Other Advanced Disease
RATIONALE: Gathering information about experiences of episodic breathlessness in patients with advanced disease may help doctors learn more about the disease.
- Conditions
- Dyspnea, Lung Cancer, Metastatic Cancer
- Trial name
- NCT01138358
- Testing
- medical chart review, study of socioeconomic and demographic variables, survey administration
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- King's College Hospital NHS Trust
Metastatic Non-Small Cell Lung Carcinoma, Solid Tumor, Adult
Perfusion-Induced Hyperthermia for Metastatic Carcinoma
The purpose of this study is to gather information on how safe the hyperthermia treatment delivered via the Exatherm-TBH (the device that will heat your blood and deliver it back to you), added to the best supportive care is to…
- Trial name
- NCT02409108
- Testing
- Exatherm-TBH system
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jonathan Kiev
ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Neoplasm of Lung
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC
This single-arm, open-label, phase II clinical study aims to evaluate the progression-Free Survival (PFS) of the combination of Alectinib plus Bevacizumab in untreated and first and second-line chemotherapy failed subjects with…
- Trial name
- NCT03779191
- Testing
- Alectinib, Bevacizumab
- Where
- Mexico
- Volunteers
- 41 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Pancreatic Cancer, Breast Cancer
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05311618
- Testing
- NGM438, Pembrolizumab (KEYTRUDA ®)
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Metastatic Non-small Cell Lung Cancer
Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA
In patients with locally advanced or metastatic tumors, first-line therapeutic management is based on the use of targeted therapies (EGFR, BRAF ALK and ROS1 inhibitors), immunotherapies (anti-PD1/ anti-PDL1-antibodies or…
- Trial name
- ELUCID (NCT03926260)
- Testing
- ctDNA analysis
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Departemental Vendee